David Lee, CEO of Singular Wings Medical, has been selected as a finalist for the “2026 Global Bio & Health Startup CEO Award”, recognized for his outstanding leadership and innovative vision in smart healthcare and digital health.
Singular Wings Medical has long focused on applying artificial intelligence (AI) to physiological signal monitoring. The team successfully developed a key technology that translates electrocardiogram (ECG) signals into continuous blood glucose values in real time, creating a completely non-invasive, painless, zero-delay, and low-consumable sustainable healthcare solution.
This breakthrough overcomes the limitations of traditional Continuous Glucose Monitoring (CGM)—which relies on invasive blood sampling or micro-needle patches—and delivers a whole new care experience for individuals with diabetes and health-conscious populations worldwide.
Special thanks to Global Bio & Investment for their in-depth coverage and recognition (Read the full report: https://news.gbimonthly.com/tw/enterprise/show.php?num=88830&page=1&kind=31 ), allowing more people to see the technological capability of Singular Wings Medical.
Singular Wings Medical will continue to deepen its research and development, advancing smart healthcare onto the global stage!
